1114529--3/16/2007--VIACELL

related topics

{product, candidate, development}

{product, liability, claim}

{cost, contract, operation}

{acquisition, growth, future}

{property, intellectual, protect}

{cost, operation, labor}

{personnel, key, retain}

{system, service, information}

{customer, product, revenue}

{product, market, service}

If we do not prevail in the PharmaStem litigation, we may be prevented from selling our ViaCord service offering, or may have to incur significant expenses. A third party could try to challenge the arbitrator s decision related to our agreement with Mothers Work. The Government of Singapore may seek to recover grant funds received by us if we do not agree to extend the term of the current grant. If we are not able to successfully develop and commercialize new products, our future prospects may be limited. We may not be able to successfully develop our ViaCyte oocyte cryopreservation product candidate. We may not be able to raise additional funds necessary to fund our operations. We depend on patents and other proprietary rights that may fail to protect our business. Third parties may own or control patents or patent applications that are infringed by our technologies or product candidates. Our success will depend in part on establishing and maintaining effective strategic partnerships and collaborations. Our cell preservation activities are subject to regulations that may impose significant costs and restrictions on us. We have only limited experience manufacturing cell therapy product candidates, and we may not be able to manufacture our product candidates in quantities sufficient for clinical studies or for commercial scale. We are dependent on our existing suppliers and establishing relationships with certain other suppliers to successfully commercialize our ViaCord service offering, for certain components of our product candidates and to manufacture and supply our ViaCyte product candidate. The loss of such suppliers or our inability to establish such relationships may inhibit our ability to commercialize ViaCord, delay development or limit our ability to manufacture our stem cell therapy products or our ViaCyte product candidate. If our cord blood processing and storage facility or our clinical manufacturing facilities are damaged or destroyed, our business, programs and prospects could be negatively affected. Our competitors may have greater resources or capabilities or better technologies than we have, or may succeed in developing better products or develop products more quickly than we do, and we may not be successful in competing with them. Due to the nature of our cell preservation activities, harm to our reputation could have a significant negative impact on our financial condition. Damage to or loss of our customers property held in our custody could potentially result in significant legal liability. The manufacture and sale of products may expose us to product liability claims for which we could have substantial liability. Our success is dependent upon recruiting and retaining qualified management and other personnel. We may face difficulties in managing and maintaining the growth of our business. Our business could be disrupted or harmed and we could be subject to liability if we are unable to operate our information systems effectively, successfully implement new technologies and protect the confidentiality of our or our customers data. If we acquire other businesses or technologies the transactions may be dilutive and we may be unable to integrate them successfully with our business, our financial performance could suffer. The successful commercialization of products may depend on patients and physicians obtaining reimbursement for products from third party payers. We face potential liability related to the privacy of health information we obtain from research collaborators or from providers who enroll patients and collect cord blood or human oocytes.

Full 10-K form ▸

1114529--3/16/2007--VIACELL_INC